NDT Advance Access published online on October 12, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh526
© 2004 by European Renal Association - European Dialysis and Transplant Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Centre for Nephrology, Royal Free Hospital, Pond Street, London NW3 2QG, UK
* To whom correspondence should be addressed. E-mail: gl.jones{at}rfc.ucl.ac.uk.
Background. Treatment of adults with idiopathic membranoproliferative glomerulonephritis (IMPGN) is often unrewarding with 60% of patients progressing to end-stage renal failure within 10 years. Although children with IMPGN may respond to steroid therapy, there is no significant benefit to treating adult IMPGN patients with immunosuppression. Methods. Outcome measures in five patients with IMPGN who were treated with oral prednisolone and mycophenolate mofetil (MMF) (treatment group) were compared with six patients with IMPGN who did not receive immunosuppression (control group). Results. There was no significant difference between either group in baseline clinical characteristics or systolic and diastolic blood pressure during observation. In the treatment group, there was a significant reduction in proteinuria from a baseline of 5.09 to 1.97 g/24 h (P = 0.003) at 6 months, 1.96 g/24 h (P = 0.003) at 12 months and 2.59 g/24 h (P = 0.015) at 18 months. There was no significant change in proteinuria over 18 months in the control group. Serum creatinine concentration and creatinine clearance did not change significantly over 18 months in the treatment group. In the control group, there were significant changes in serum creatinine and creatinine clearance over 18 months [baseline 103 to 159 µmol/l (P = 0.004) and baseline 108 to 67 ml/min (P>0.001), respectively] when compared to baseline, although the differences were not significant when the two groups were compared directly. Conclusions. This preliminary study suggests that in the short term, the combination of MMF and prednisolone can significantly reduce proteinuria and may preserve renal function in patients with IMPGN.
Accepted September 7, 2004
Brief Report
Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Segarra, M L. Amoedo, J. M Martinez Garcia, S. Pons, M. Praga, E. I. Garcia, J. C. Alonso, J. M. Gasco, L. Pou, and L. Piera Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--A multicenter study Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1351 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019. [Full Text] [PDF]
|
|
|
|
 |
|
 P S Patel and I R Rifkin Mycophenolate and nephrology Lupus, November 1, 2006; 15(11_suppl): 39 - 43. [Abstract] [PDF]
|
|
|
|
|
|
M Y Karim and I C Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, March 1, 2005; 14(3_suppl): s39 - s41. [Abstract] [PDF]
|
|
|
|
|
|
M. Karim and I. Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, January 1, 2005; 14(1_suppl): s39 - s41. [Abstract] [PDF]
|
|